Baxter International (BAX)
(Delayed Data from NYSE)
$36.91 USD
-1.06 (-2.79%)
Updated Oct 1, 2024 04:00 PM ET
Pre-Market: $36.91 0.00 (0.00%) 8:14 AM ET
2-Buy of 5 2
A Value F Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$36.91 USD
-1.06 (-2.79%)
Updated Oct 1, 2024 04:00 PM ET
Pre-Market: $36.91 0.00 (0.00%) 8:14 AM ET
2-Buy of 5 2
A Value F Growth B Momentum C VGM
Zacks News
Why Baxter (BAX) Could Beat Earnings Estimates Again
by Zacks Equity Research
Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Medical Products Stocks Poised to Beat This Earnings Season
by Trina Mukherjee
The Medical Products companies' Q4 results are likely to reflect base business recovery. Let's see how BAX, HSIC, and XRAY are poised ahead of their earnings releases.
Is Baxter International (BAX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Baxter International (BAX) and Gamida Cell (GMDA) have performed compared to their sector so far this year.
BD (BDX) Beats on Q1 Earnings and Revenues, Raises FY22 View
by Zacks Equity Research
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal first quarter.
Abiomed (ABMD) Beats on Q3 Earnings, Narrows FY22 Guidance
by Zacks Equity Research
Abiomed's (ABMD) strength in Impella product revenues drives its Q3 top line.
McKesson (MCK) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
McKesson's (MCK) fiscal third-quarter 2022 results benefit from considerable growth across all segments.
Change Healthcare (CHNG) Q3 Earnings in Line, Revenues Beat
by Zacks Equity Research
Change Healthcare's (CHNG) fiscal third-quarter results benefit from solid performance across Software and Analytics, Network Solutions and Technology-Enabled segments.
Cardinal Health (CAH) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cardinal Health's (CAH) fiscal second-quarter results benefit from a solid performance in the Pharmaceutical segment.
Boston Scientific (BSX) Q4 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in legacy business from pandemic mayhem.
AmerisourceBergen (ABC) Q1 Earnings Lag Estimates, Revenues Beat
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal first-quarter results benefit from segmental growth.
PerkinElmer (PKI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter results benefit from solid performance at Discover & Analytics Solutions business.
Catalent (CTLT) Q2 Earnings Top Estimates, FY22 View Up
by Zacks Equity Research
Catalent's (CTLT) robust performance across most of its segments drives its second-quarter fiscal 2022 top line.
Quest Diagnostics (DGX) COVID Test Sales Aid Amid Price Woe
by Zacks Equity Research
Quest Diagnostics' (DGX) base business continues to improve, signifying the ongoing recovery trend of the industry.
NextGen's (NXGN) Integrated Platform to Enhance Tribal Health
by Zacks Equity Research
NextGen's (NXGN) integrated platform was adopted by a community health center in Northern California to meet the health requirements of American Indians/Alaska Natives.
CVS Health (CVS) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Strength across the retail segment and growing specialty pharmacy revenues are driving CVS Health's (CVS) top line.
Thermo Fisher (TMO) Base Sales Rebound, Bioproduction in Focus
by Zacks Equity Research
Thermo Fisher (TMO) is currently expanding its bioproduction purification resin capacity, which is used in the mRNA manufacturing process.
Here's Why You Should Invest in Henry Schein (HSIC) Now
by Zacks Equity Research
Investors are optimistic about Henry Schein's (HSIC) strong segmental performance and raised 2021 EPS guidance.
The Zacks Analyst Blog Highlights: Roche Holding, Pfizer, Baxter International, STMicro and Philips
by Zacks Equity Research
Roche Holding, Pfizer, Baxter International, STMicro and Philips are included in this analyst blog.
Veeva Systems (VEEV)-LYSARC Partner to Advance Lymphoma Therapy
by Zacks Equity Research
Veeva Systems' (VEEV) Veeva Development Cloud will allow LYSARC to develop innovative lymphoma therapies or enhance current therapies.
Oxygen from Earnings: Global Week Ahead
by John Blank
In the Global Week Ahead, Q4 S&P500 earnings will supply the latest details on how major global companies are dealing with rising wage cost pressures.
Medtronic (MDT) Undertakes Investment to Advance STEM Education
by Zacks Equity Research
The Medtronic Foundation, solely funded by Medtronic plc (MDT), entered into 13 new partnerships to bridge the inequity in STEM education among underrepresented and underserved communities.
Catalent (CTLT) to Advance Oral Drug Development With New Launch
by Zacks Equity Research
Catalent's (CTLT) Xpress Pharmaceutics service offers a quicker alternative to the traditional clinical development model, lowering the time needed to complete clinical studies.
Here's Why You Should Retain Chemed (CHE) Stock for Now
by Zacks Equity Research
Investors are optimistic about Chemed (CHE), given impressive performance of the Roto-Rooter arm and solid growth in VITAS admissions.
Abiomed (ABMD) Reports Positive Data Backing preCARDIA System
by Zacks Equity Research
Abiomed's (ABMD) preCARDIA system has proven to be effective in reducing cardiac filling pressures and increasing urine output in ADHF patients.
Is ATI Physical Therapy, Inc. (ATIP) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how ATI Physical Therapy, Inc. (ATIP) and Baxter International (BAX) have performed compared to their sector so far this year.